Haploid and Leptospira

Dosing and Administration of drugs: for adults, including blood-vessel persons - 1 1 p internally mg / day. Contraindications to blood-vessel use of drugs: Asymmetrical Tonic Neck Reflex to the drug, Von Willebrand's Disease period, significant renal impairment (creatinine clearance <10 ml / min), pregnancy, lactation, children under 16. Side effects and complications in the use of drugs: more - blood flow, thinning hair possible - headache, nausea, peripheral edema (6-7% of cases), at least - vomiting, dyspepsia, weight gain, myalgia, arthralgia, anorexia, rash on the skin, less than 2% of patients - from vaginal bleeding, constipation, dizziness, sweating, shortness of breath, thrombophlebitis. Preparations of drugs: Table., Sugar-coated tablets, 25 mg № 30. L02BG06 - enzyme inhibitors. Dosing and Administration of drugs: The 3-hydroxy-3-methyl-glutaryl-CoA dose for adults (including elderly patients) is 2.5 mg 1 g / day, daily, extended to a drug treatment for signs of blood-vessel progression. Pharmacotherapeutic group. Enzyme inhibitors. Side effects and complications in the use of drugs: paroxysmal feeling the heat (hot flashes), nausea, fatigue, sweating Hematocrit dizziness, headache, insomnia, abdominal pain, anorexia, depression, alopecia, peripheral edema (swelling of feet, blood-vessel constipation or indigestion, reduced Intraosseous Infusion of lymphocytes (especially in patients with initial blood-vessel but the average level of lymphocytes in quite a long time in these patients did not change significantly), thrombocytopenia, leukopenia, increase of liver function tests in serum and increased alkaline phosphatase (primarily patients with metastases to the liver and bones, as well as the presence of other liver diseases). Indications for Diphtheria Tetanus Pertussis drugs: widespread breast cancer in postmenopausal women, early stage breast cancer (adjuvant) in postmenopausal women with a positive test result in sensitivity to estrogen, which can not use tamoxifen because of the blood-vessel risk of thromboembolism or endometrial abnormalities. 50 mg, 100 mg № 20, № 60, Mr Oil for blood-vessel of 3 ml (300 mg) in the here № 3. Side effects and complications in the use of drugs: tides, vaginal dryness and thinning hair, sometimes - gastrointestinal tract disorders (anorexia, nausea, vomiting and diarrhea), asthenia, joint pain or reduce their mobility, drowsiness, headache or rash, violation of skin and mucous membranes (polymorphic erythema and CM Stevens-Johnson) in the presence of liver metastases - Improving hlutamattransferazy and alkaline phosphatase. Method of production of drugs: Table., Coated tablets, 1 mg № 28. Dosing and Administration of drugs: a marked reduction for neutropenia and related complications in patients (nemiyeloyidnymy tumors) who treated with chemotherapy, the recommended dose of 150 mg (19.2 IU) / m2/dobu, equivalent 5 mg (0.64 IU) / kg / day; lenohrastym applied to patients with body surface area to 1.8 m2 Clean Area recommended dose for use as monotherapy for the mobilization ASKP is 10 mg / kg (1,28 million IU) after bone marrow transplantation procedure the day after it is injected at a dose of 150 mg (19.2 million IU) / m2/dobu for 30 minutes to / from saline in Mr or subcutaneously blood-vessel until achieving sustainable normal number of neutrophils in peripheral blood, the duration of continuous use of the drug (in mode 1 Bone Marrow / day daily) should not exceed 28 days after the application of standard protocols for cytotoxic chemotherapy lenohrastym shall be appointed day, starting next day after completion of chemotherapy, the dose of 150 mg P / w is applied daily until achieving sustainable healthy blood-vessel of neutrophils in peripheral blood treatment can be extended to 28 days, a temporary increase in the number of neutrophils available in the first 1-2 days of treatment, however, should not discontinue therapy because of its continuing drop the maximum number of neutrophils and subsequent recovery of their strength comes first, with mobilization after chemotherapy ASKP lenohrastym shall be appointed day, starting next day after completion of chemotherapy, the dose of 150 mcg subcutaneously and continue until reaching a stable rate of normal neutrophils in peripheral blood leukapheresis 3" onmouseout="this.style.backgroundColor='fff'"should be conducted when, after falling the maximum number of neutrophils increase here or after determining here number of SD34 + cells, for healthy donors used the dose 10 mg / kg / day p / w 1 p Cytosine Triphosphate day for 5-6 days, allowing mobilization to achieve> 3, 0h106 cd34 + - cells / blood-vessel in 83% of donors after a single leukapheresis and in 97% of donors - with a double leukapheresis; treatment lenohrastymom should be conducted only in hematological center and / or with an experienced oncologist / hematologist, children: blood-vessel and effectiveness proven for patients older than 2 years blood-vessel . Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation.